vr

Vertex Pharmaceuticals

VRTX
NASDAQ
$465.07

How predictable is Vertex Pharmaceuticals's business?

CF remains a recurring, chronic therapy base that has delivered double‑digit revenue growth and high visibility. We estimate TTM revenue through Q2 2025 at about 11.4 billion dollars (Q3 2024 2.77B, Q4 2024 2.91B, Q1 2025 2.77B, Q2 2025 2.96B).

New launches add diversification but introduce some adoption variability, particularly Journavx within acute pain and the stepwise nature of gene therapy volumes. Overall, predictability is high relative to biotech peers, though less than tollbooth‑like networks.

Read the full report on Vertex Pharmaceuticals and explore the other sections

Overview
Overview of Vertex Pharmaceuticals
Moat
Does Vertex Pharmaceuticals have a strong competitive moat?
Pricing Power
Does Vertex Pharmaceuticals have pricing power in its industry?
Predictability
How predictable is Vertex Pharmaceuticals's business?
Financial Strength
Is Vertex Pharmaceuticals financially strong?
Capital Allocation
How effective is Vertex Pharmaceuticals's capital allocation strategy?
Management
Does Vertex Pharmaceuticals have high-quality management?
Fair Value
What is the fair value of Vertex Pharmaceuticals stock?